Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Read More…
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Phone574-267-6131
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$7.93 billion
Profitability
Miscellaneous
Employees19,000
Next Earnings Date11/5/2019 (Confirmed)
OptionableOptionable
Zimmer Biomet (NYSE:ZBH) Frequently Asked Questions
What is Zimmer Biomet's stock symbol?
Zimmer Biomet trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH."
How often does Zimmer Biomet pay dividends? What is the dividend yield for Zimmer Biomet?
Zimmer Biomet announced a quarterly dividend on Tuesday, September 3rd. Shareholders of record on Monday, September 30th will be paid a dividend of $0.24 per share on Thursday, October 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.70%. The ex-dividend date is Friday, September 27th. View Zimmer Biomet's Dividend History.
How were Zimmer Biomet's earnings last quarter?
Zimmer Biomet Holdings Inc (NYSE:ZBH) issued its earnings results on Friday, July, 26th. The medical equipment provider reported $1.93 EPS for the quarter, beating the Zacks' consensus estimate of $1.91 by $0.02. The medical equipment provider had revenue of $1.99 billion for the quarter, compared to analysts' expectations of $1.98 billion. Zimmer Biomet had a negative net margin of 4.56% and a positive return on equity of 13.40%. The company's quarterly revenue was down .9% on a year-over-year basis. During the same quarter last year, the company posted $1.92 earnings per share. View Zimmer Biomet's Earnings History.
When is Zimmer Biomet's next earnings date?
How can I listen to Zimmer Biomet's earnings call?
Zimmer Biomet will be holding an earnings conference call on Tuesday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Zimmer Biomet issued on next quarter's earnings?
Zimmer Biomet issued an update on its FY19 earnings guidance on Friday, July, 26th. The company provided EPS guidance of $7.75 -7.90 for the period, compared to the Thomson Reuters consensus estimate of $7.80. The company issued revenue guidance of $7.94 billion, compared to the consensus revenue estimate of prior $7.70-7.90.
What price target have analysts set for ZBH?
23 brokerages have issued 12-month price objectives for Zimmer Biomet's shares. Their predictions range from $108.00 to $170.00. On average, they expect Zimmer Biomet's share price to reach $145.25 in the next twelve months. This suggests a possible upside of 6.5% from the stock's current price. View Analyst Price Targets for Zimmer Biomet.
What is the consensus analysts' recommendation for Zimmer Biomet?
23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last year. There are currently 1 sell rating, 4 hold ratings and 18 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zimmer Biomet.
What are Wall Street analysts saying about Zimmer Biomet stock?
Here are some recent quotes from research analysts about Zimmer Biomet stock:
- 1. According to Zacks Investment Research, "Zimmer Biomet ended the quarter on a strong note with better-than-expected results. However, the year-over-year performance remained sluggish. The company witnessed strength in the Europe, Middle East and Africa and Asia-Pacific region as well as in the S.E.T. and Dental businesses. Zimmer Biomet is executing well within its priority areas like quality remediation, supply recovery efforts and product launches. In terms of product launch, the strong rollout of ROSA, mymobility and Persona Partial and Cementless are clearly among major achievements. Zimmer Biomet has outperformed its sector in the past six months. However, sales in Americas remained sluggish. Escalating costs and expenses are denting the adjusted operating margin for the company. Adverse currency movements continue to be a concern. Declining dental sales at CER also disappoint." (8/31/2019)
- 2. BTIG Research analysts commented, "an easy comp led us to believe that 3Q results were beatable. While top-line fell in-line with the Street and EPS was 3 cents higher (which would have satisfied investors in our view), sentiment was hampered by commentary related to FY19 (specifically ongoing margin pressures and lost sales from ZBH’s distribution agreement with BONESUPPORT (BONEX-OM, Not Rated)). Underlying rev. growth of 2.0% Y/Y improved Y/Y (helped by 3Q tenders, ~40bps by our est.) and while GMs were soft (as expected in 3Q), mgmt. commentary indicates ongoing margin pressure into FY19 along with increasing Fx headwinds. Collectively headwinds will lower EPS by $0.15 in FY19, offset by a lower interest expense and tax rate." (10/28/2018)
Has Zimmer Biomet been receiving favorable news coverage?
News headlines about ZBH stock have trended negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Zimmer Biomet earned a news sentiment score of -2.6 on InfoTrie's scale. They also assigned media headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Zimmer Biomet.
Who are some of Zimmer Biomet's key competitors?
Some companies that are related to Zimmer Biomet include Intuitive Surgical (ISRG), Edwards Lifesciences (EW), COLOPLAST A/S/ADR (CLPBY), Smith & Nephew (SNN), Align Technology (ALGN), Steris (STE), DEMANT A S/ADR (WILYY), MSA Safety (MSA), Wright Medical Group (WMGI), Avanos Medical (AVNS), Inogen (INGN), Establishment Labs (ESTA), Sientra (SIEN), Invacare (IVC) and RTI Surgical (RTIX).
What other stocks do shareholders of Zimmer Biomet own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Zimmer Biomet investors own include Celgene (CELG), AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Visa (V), General Electric (GE), UnitedHealth Group (UNH), Bristol-Myers Squibb (bmy), Chevron (CVX) and Merck & Co., Inc. (MRK).
Who are Zimmer Biomet's key executives?
Zimmer Biomet's management team includes the folowing people:
- Mr. Bryan C. Hanson, Pres, CEO & Director (Age 52)
- Mr. Daniel P. Florin Sr., Exec. VP & CFO (Age 55)
- Mr. Chad F. Phipps, Sr. VP, Gen. Counsel & Sec. (Age 47)
- Mr. Sang Yi, Pres of Asia Pacific (Age 57)
- Mr. Ivan Tornos, Group Pres of Orthopedics (Age 43)
Who are Zimmer Biomet's major shareholders?
Zimmer Biomet's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Perpetual Ltd (0.03%), State of Alaska Department of Revenue (0.02%), Gulf International Bank UK Ltd (0.02%), Welch & Forbes LLC (0.01%), Pacer Advisors Inc. (0.01%) and Bridge Creek Capital Management LLC (0.01%). Company insiders that own Zimmer Biomet stock include Arthur J Higgins, Betsy J Bernard, Bryan C Hanson, Chad F Phipps, Didier Deltort, Katarzyna Mazur-Hofsaess, Michael J Farrell, Michael W Michelson, Sang Yi, Syed A Jafry and Tony W Collins. View Institutional Ownership Trends for Zimmer Biomet.
Which institutional investors are selling Zimmer Biomet stock?
ZBH stock was sold by a variety of institutional investors in the last quarter, including Rothschild Investment Corp IL, Perpetual Ltd, Lau Associates LLC, Cerebellum GP LLC, Enterprise Trust & Investment Co, Crossmark Global Holdings Inc., Bridge Creek Capital Management LLC and Gulf International Bank UK Ltd. Company insiders that have sold Zimmer Biomet company stock in the last year include Chad F Phipps, Didier Deltort and Sang Yi. View Insider Buying and Selling for Zimmer Biomet.
Which institutional investors are buying Zimmer Biomet stock?
ZBH stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Private Trust Co. NA, Pacer Advisors Inc., Northstar Investment Advisors LLC, Town & Country Bank & Trust CO dba First Bankers Trust CO, Perkins Coie Trust Co, First Hawaiian Bank and North Star Investment Management Corp.. Company insiders that have bought Zimmer Biomet stock in the last two years include Arthur J Higgins, Betsy J Bernard, Bryan C Hanson, Michael J Farrell, Michael W Michelson and Syed A Jafry. View Insider Buying and Selling for Zimmer Biomet.
How do I buy shares of Zimmer Biomet?
Shares of ZBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Zimmer Biomet's stock price today?
One share of ZBH stock can currently be purchased for approximately $136.44.
How big of a company is Zimmer Biomet?
Zimmer Biomet has a market capitalization of $28.01 billion and generates $7.93 billion in revenue each year. The medical equipment provider earns $-379,200,000.00 in net income (profit) each year or $7.64 on an earnings per share basis. Zimmer Biomet employs 19,000 workers across the globe.View Additional Information About Zimmer Biomet.
What is Zimmer Biomet's official website?
How can I contact Zimmer Biomet?
Zimmer Biomet's mailing address is 345 EAST MAIN STREET, WARSAW IN, 46580. The medical equipment provider can be reached via phone at 574-267-6131 or via email at [email protected]
MarketBeat Community Rating for Zimmer Biomet (NYSE ZBH)
MarketBeat's community ratings are surveys of what our community members think about Zimmer Biomet and other stocks. Vote "Outperform" if you believe ZBH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZBH will underperform the S&P 500 over the long term. You may vote once every thirty days.
